Clinical Research Trials

Browse trials that we are currently enrolling for by condition and associated pharmaceutical company.

Nonalcoholic Steatohepatitis (NASH)


VK2809 a phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with biopsy proven non-alcoholic steatohepatitis with fibrosis(stage 1-3).

Learn More


A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH).

Learn More


A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis.

Learn More

AURORA (Allergan)

This is a Phase 3 study for the treatment of Stage 2 to 3 liver fibrosis in adult subjects with NASH. Must have a liver biopsy or have a historical one performed 6 months prior to screening.

Learn More


A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) stage 2-3 with Type 2 Diabetes.

Learn More

Ulcerative Colitis

Eli Lilly (AMAN)

Phase 3 Study for Patients with Moderately to Severely Active Ulcerative Colitis. Must have failed 1 biologic.

Learn More


A Multicenter Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis.

Learn More


Eli Lilly (AMAM)

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-and Active Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderately to Severely Active Crohn’s Disease.

Learn More


A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 as Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease.

Learn More


A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction Therapy in Subjects With Moderately to Severely Active Crohn’s Disease.

Learn More



Phase 2b Dose Response, Efficacy and Safety Study in Adult Subjects with Symptomatic Idiopathic or Diabetic Gastroparesis.

Learn More

Screening Colonoscopy


The GuardantLUNAR-2 test is an NGS-based plasma assay which derives a binary qualitative result for a patient’s risk of colorectal cancer.  No results from the test will be returned to either the patient or the investigator and therefore no treatment decisions will be based upon the results.

Learn More

The physicians at Digestive Healthcare of Georgia are closely monitoring the coronavirus (COVID-19) outbreak. In the interest of everyone’s health and safety we ask all patients and their guests who have a fever (100° or above), symptoms of a respiratory infection, or who may have traveled to a restricted country or may have been exposed to a person with known COVID-19, the flu or any other communicable disease to reschedule their appointments or procedures. You will not be charged for canceling/rescheduling your appointment. We will be following CDC and Georgia Department of Public Health’s recommendations for screening and management of patients. If you are at all concerned you may have a serious infectious disease, your best course of action is to seek care at your primary care physician’s office or local hospital’s emergency department.

We have implemented a telemedicine visit for our patients who are unable to be in the office for their appointment. Please call our office to schedule a telemedicine visit with your provider.